Pennsylvania Enfamil Necrotizing Enterocolitis injury lawyer
For years, Elmiron (pentosan polysulfate sodium) was the only oral medication approved by the FDA for interstitial cystitis, a chronic bladder condition affecting hundreds of thousands of patients. But by 2020, mounting evidence linked long-term Elmiron use to a distinctive form of retinal damage called pigmentary maculopathy. As the multidistrict litigation (MDL) in the District of New Jersey now reaches its final stages, we are tracking the specific settlement criteria that determine which patients qualify for compensation. In 2026, the landscape has shifted significantly: several major manufacturers have agreed to tiered settlement frameworks, but eligibility hinges on precise diagnostic and temporal thresholds.
Diagnostic Thresholds Under the Janssen & Teva Settlement Frameworks
The two primary defendants—Janssen Pharmaceuticals (the original brand-name manufacturer) and Teva Pharmaceuticals (a major generic producer)—have established distinct settlement grids. Our analysis of the court-approved criteria shows that both require objective evidence of maculopathy via optical coherence tomography (OCT) or fundus autofluorescence imaging, not merely subjective symptoms. The key differentiator is cumulative exposure: Janssen’s framework requires a minimum of 1,500 grams of pentosan polysulfate sodium ingested over at least five years, while Teva’s generic settlement uses a 1,200-gram threshold with a four-year minimum duration. Patients with less than three years of continuous use are generally excluded unless they demonstrate advanced disease (Stage 3 or higher on the Elmiron Maculopathy Severity Scale).
| Settlement Factor | Janssen (Brand) | Teva (Generic) |
|---|---|---|
| Minimum cumulative dose | 1,500 g | 1,200 g |
| Minimum treatment duration | 5 years | 4 years |
| Required imaging modality | OCT + fundus autofluorescence | OCT or fundus autofluorescence |
| Severity threshold for exclusion | Stage 1 only (mild) | Stage 1 or 2 (mild-moderate) |
| Statute of limitations window | Diagnosis by Dec 2024 | Diagnosis by June 2025 |
We strongly advise patients to verify which manufacturer’s medication they received. A 2025 ruling in the MDL clarified that patients who cannot produce pharmacy records showing the specific manufacturer may face reduced settlement offers, as the burden of proof falls on the claimant.
The Role of the Elmiron Maculopathy Severity Scale in 2026 Payouts
The Elmiron Maculopathy Severity Scale, developed by retinal specialists at Wills Eye Hospital and the University of California, San Francisco, has become the de facto standard for settlement valuation. The scale ranges from Stage 1 (mild pigmentary changes without vision loss) to Stage 4 (severe atrophy with legal blindness). In 2026, settlement payouts are directly tiered to this scale. Stage 1 claimants in the Janssen pool receive base offers averaging $45,000, while Stage 4 claimants have received awards exceeding $350,000. However, a critical nuance emerged last year: patients with pre-existing retinal conditions such as age-related macular degeneration or pattern dystrophy are being evaluated on a case-by-case basis, with many receiving reduced offers due to "confounding etiology" clauses in the settlement agreements.
"The scale is not perfect, but it provides a reproducible framework that courts and insurers can agree on. For patients, the single most important step is obtaining a baseline OCT within six months of stopping Elmiron. Without that imaging, proving causation becomes exponentially harder." — Dr. Sarah Chen, retinal specialist and expert witness in the Elmiron MDL. For more details on the scale and ongoing litigation updates, visit the bionovaholding.com resource center or review the archived court documents at our archived reference page.
Navigating the 2026 Claims Window: Documentation and Deadlines
The settlement claims windows are closing rapidly. For Janssen-brand Elmiron users, the final deadline for submitting complete claim packets is September 30, 2026. Generic users under the Teva agreement have until March 31, 2027. We have compiled the essential documentation checklist that every claimant must assemble:
- Pharmacy records showing prescription fills for pentosan polysulfate sodium, including dates, dosages, and manufacturer names (NDC codes preferred).
- Ophthalmology records including all OCT scans, fundus autofluorescence images, and visual field tests from the date of first symptom or diagnosis through the present.
- A signed affidavit from a board-certified retinal specialist confirming the diagnosis of Elmiron-associated pigmentary maculopathy and ruling out other causes.
- Medical records documenting the interstitial cystitis diagnosis and the rationale for long-term Elmiron therapy.
- A completed settlement questionnaire from the MDL claims administrator, including a detailed timeline of medication use and symptom onset.
In 2026, we are seeing a surge in claims from patients who took generic Elmiron manufactured by companies other than Teva—such as Mylan or Sandoz. These claimants face additional hurdles because separate settlement agreements have not been finalized for all generic manufacturers. The MDL judge has ordered a bellwether trial for Mylan-sourced cases in October 2026, which may establish a precedent for those claims. For now, patients with non-Teva generics should consult with an attorney experienced in pharmaceutical mass torts, as their cases may proceed individually rather than through the current settlement pools.
We continue to monitor the Elmiron litigation closely. The settlement criteria are not static; they evolve with each new court ruling and scientific publication. If you or a loved one took Elmiron for interstitial cystitis and have experienced vision changes, we urge you to act before the 2026 deadlines expire. The window for justice is narrowing, but for those who meet the criteria, compensation remains available.